Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2012

View Archived Issues

Amgen offers pipeline update for first quarter 2012

GSK reflects on achievements of first quarter 2012

U.K. study reveals new potential marker of acute kidney injury in acute on chronic liver failure

Promising candidate biomarker of venous thrombosis uncovered

Responses to sodium oxybate vary in phase I/II trial

FDA approves sNDA for Votrient

Afinitor approved in U.S. for new indication

Novel PLK1 inhibitor exhibits antitumor activity in vivo

Double-blind trial assesses extended-release once-daily epilepsy drug

Shionogi submits NDA for tablets to treat vulvar and vaginal atrophy

BioAlliance Pharma provides update on AMEP biotherapy

Repligen reports on RG-1068 NDA

Sanofi vaccine approved in Japan to prevent acute flaccid poliomyelitis

Orphan drug reverses vision loss in patients with Leber's hereditary optic neuropathy

Novel telomerase inhibitors developed at Pharminox

Almirall presents new SYK/JAK inhibitors

Proximagen designs novel chemokine CCR2 receptor antagonists

New monoamine reuptake inhibitors discovered in China

Kissei Pharmaceutical patents new indolizine derivatives

FDA approves new product to treat erectile dysfunction

Manhattan Pharmaceuticals to change name

Pivotal macitentan study meets primary endpoint

Athersys discusses development of cell therapy with FDA

Trimel gives update on special population study of male hypogonadism treatment

Algeta and Sanofi extend research collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...